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Abstract
Background—Advantages offered by canine population substructure, combined with clinical
presentations similar to human disorders, makes the dog an attractive system for studies of cancer
genetics. Cancers that have been difficult to study in human families or populations are of
particular interest. Histiocytic sarcoma is a rare and poorly understood neoplasm in humans that
occurs in 15–25% of Bernese Mountain Dogs (BMD).
Methods—Genomic DNA was collected from affected and unaffected BMD in North America
(NA) and Europe. Both independent and combined genome wide association studies (GWAS)
were used to identify cancer-associated loci. Fine mapping and sequencing narrowed the primary
locus to a single gene region.
Results—Both populations shared the same primary locus, which features a single haplotype
spanning MTAP and part of CDKN2A and is present in 96% of affected BMD. The haplotype is
within the region homologous to human chromosome 9p21, which has been implicated in several
types of cancer.
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Conclusions—We present the first GWAS for HS in any species. The data identify an
associated haplotype in the highly cited tumor suppressor locus near CDKN2A. These data
demonstrate the power of studying distinctive malignancies in highly predisposed dog breeds.
Impact—Here, we establish a naturally-occurring model of cancer susceptibility due to CDKN2
dysregulation, thus providing insight regarding this cancer-associated, complex, and poorly
understood genomic region.
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Introduction
Although many genes have been associated with rare, high-penetrance cancer syndromes in
humans, such syndromes account for only a fraction of familial cancer risk (1). A recent
explosion of genome wide association studies (GWAS) has identified several putative
cancer-associated risk alleles, many of which are located near known cancer genes, although
not within classic exonic boundaries (reviewed in:(2)). These non-coding, low-penetrance,
cancer-susceptibility alleles likely contribute to quantitative changes in gene expression and,
as such, are difficult to find.
Dogs are particularly well-suited to studies of malignancy (3) as cancer is the most frequent
cause of disease-associated death in dogs, and naturally occurring, cancers are well-
described in several breeds (4, 5). The high incidence of breed-specific cancers offers
opportunities to identify sequence variants leading to disease susceptibility that have been
difficult to find in humans. Application of the canine system is particularly efficacious when
multiple closely related breeds or pure breeding populations of the same breed exist, each
with predisposition to the same disease and as such, are likely to segregate the same founder
mutation (6, 7), (8).
Histiocytic sarcoma (HS) is a highly aggressive and lethal dendritic cell neoplasm that
occurs in 15–25% of BMD (9–12). Localized HS most commonly develops in the skin or
subcutis of an extremity. The tumor is locally invasive with metastasis to lymph nodes and/
or blood vessels. Disseminated HS is a multi-system disease with tumors appearing in
numerous organs including the spleen, liver and lungs. Progression to death is rapid (12).
Almost no information is known about the genetic underpinnings HS in humans or animals
(13), largely due to the lack of a well-characterized biological system for study. In this paper
we summarize findings from two independent histiocytic sarcoma GWAS in BMDs,
offering insights into this poorly understood class of neoplasms as well as establishing a
foundation for future studies of histiocytoses in humans.
Materials and Methods
Sample collection
All dog owners provided informed consent consistent with Animal Care and Use
Committees at their collecting institution. DNA was isolated from 475 BMD blood samples.
Two hundred forty, 95 and 140 were provided from NA, France and The Netherlands,
respectively. All dogs with available pedigree data were unrelated at the grandparent level.
For detailed collection information see Supplemental Materials S1. Whole blood was
collected with either EDTA or ACD anticoagulant. In NA and The Netherlands, genomic
DNA was isolated using a standard phenol-chloroform protocol (14). In France the Nucleon
BACC Genomic DNA Extraction Kit was used (GE Healthcare, Piscataway, NJ). All
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samples were stripped of identifiers, numerically coded, and aliquoted for long-term storage
at −80°C.
Genotyping and PCA
Samples were genotyped using the Canine SNP20 Beadchip panel (Illumina, San Diego,
CA) which included ~22,000 SNPs. After removing SNPs with a minor allele frequency
<0.01 and genotyping rate <80%, 17,218 SNPs remained. The final data set included 114
and 120 case and control dogs, respectively, from North America (NA), and 128 and 112,
respectively from Europe. More than 96% of European dogs came from France and The
Netherlands. Two rounds of principal components analysis (PCA) were performed on the
dataset using EIGENSTRAT (15). The first removed genetic outliers and the second
determined the amount of stratification within the dataset. Eight dogs were removed because
they were >6 standard deviations from the average across the top 10 PCs. The remaining
466 dogs (228 NA and 238 European) were clustered according to the top 10 PCs. The
process was repeated in the NA and the European samples independently, and two
additional outliers were removed. Fst values and inbreeding coefficients were calculated by
continents, countries, and case/control status. The complete dataset of genotypes and
phenotypes is available by request sent to dog_genome@mail.nih.gov.
GWAS analyses
In the first of two GWAS, 111 case and 117 control BMD from NA were analyzed using
PLINK v1.07 (16). Standard χ2 values of association were calculated (17). Spurious missing
data was imputed using BEAGLE and the analysis repeated, correcting for multiple testing
with 10,000 permutations using PRESTO (18, 19). The data were analyzed using EMMA to
correct for stratification and cryptic relatedness (20).
In the second GWAS, 125 European cases and 111 controls were analyzed using the same
methods. The two NA and European GWAS results were compared and the datasets
combined. Association was calculated without correction in PLINK, stratified by continent
and permuted 10,000 times in PRESTO, and corrected for population structure using an
additive kinship matrix implemented by EMMA. Loci that were significantly associated
with disease in both populations were considered further.
Fine mapping
A custom SNPlex genotyping assay was run on 175 case and 162 control BMDs from NA
(213) and Europe (124) (Applied Biosystems, Foster City, CA). Selected SNPs spanned 9.7
Mb (chr11:39,072,460-48,846,456) and surrounded highly associated markers from the
combined GWAS. After removing failed and uninformative SNPs, 229 remained
(Supplemental Table S2).
Genotypes from SNPlex were imputed on all 466 dogs from the original GWAS using
BEAGLE (18, 21). Because the datasets were divided by continent before imputation to
account for differences in population structure, an additional 212 SNPs were added to the
original GWAS data and association was calculated, as previously described. Phasing and
association was performed using BEAGLE. Finally, the datasets were combined and
association calculated with correction for population structure across the genome, including
and excluding chromosome 11. Frequency of the associated haplotype was calculated in
cases and controls from each population.
Sequencing
Amplicons were sequenced within a 300 kb region (chr11:44,001,369-44,331,631) that
included the 198kb (chr11:44,133,881-44,331,630) associated haplotype and all predicted
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exons of CDKN2A, CDKN2B, and MTAP. Primers were designed using Primer3 v0.4.0
(22) (Supplemental Table S2). Segments were amplified from 24 case and 20 control NA
BMD using standard protocols and sequenced using BigDye Terminator v3.1 on an ABI
3730xl DNA Analyzer (Applied Biosystems). Sequencing 306 amplicons revealed 133
SNPs. The complete sequence of the INK4A transcript and the genomic sequence of
CDKN2A exon1a and promoter have been submitted to NCBI GenBank (accession numbers
JN086563 and JN086564, respectively).
Sequences were analyzed using Phred/Phrap/Consed (23–25) with SNPs identified by
Polyphred (26). BEAGLE was used to estimate haplotypes, impute genotypes, and calculate
Fisher’s exact association for SNPs and haplotypes after 10,000 permutations (21, 27). The
sequenced SNPs were imputed on the NA SNPlex dataset to calculate association. Markers
with >25% missing data were removed prior to imputing. Pairwise LD and haplotype block
analysis was performed using Haploview v4.1 (28).
To confirm the relative strength of SNP associations from imputed data, nine SNPs were
genotyped in an additional 109 cases and 89 controls (Supplemental Table S3). Also, ten
dogs from seven non-HS breeds were genotyped with the same SNPs.
Quantitative PCR in dendritic cells from healthy dogs
Four ml blood samples were obtained from 53 healthy BMD, randomly selected from ~500.
Peripheral mononuclear cells (PBMC) were isolated, uniformly plated, and allowed to
expand in the presence of IL-4 (50 ng/ml) and GM-CSF (33ng/ml) in order to select for
dendritic precursor cells (29, 30). At 19 days, the cells were harvested and DNA/RNA were
extracted using standard methods.
Samples were assigned haplotypes based on their genotypes at chr11:44,201,923 and
44,215,162. Pre-designed Taqman assays were obtained for the B2M (endogenous control)
and MTAP genes while primers and probe were designed for CDKN2A and CDKN2B using
Primer Express (Applied Biosystems). Real-time PCR was performed on 24 ng of cDNA for
each assay using standard protocols. Each sample was run in triplicate and CT values
averaged. Relative quantities of the transcripts and average fold change were calculated
using the ΔCt method compared to an endogenous control and a reference tissue (testis) and
then corrected for amplification efficiency (31, 32). Data was collected for six dogs
homozygous for the CA haplotype, six heterozygous dogs, and five dogs lacking the CA
haplotype. P-values were calculated for the differences in distributions of transcript




PCA of the entire dataset of 474 dogs and 17,218 SNPs revealed significant stratification
among the populations of BMD from NA and EU (Figure 1c). Plots of PCs 1 and 2 show
separation of NA and EU populations (Figure 1a) while cases and controls are fully
integrated (Figure 1b). Calculations of Fst averaged over all loci show that divergence
between cases and controls is an order of magnitude lower than between geographic
localities (average Fst=0.001 and 0.015, respectively). Overall, NA dogs demonstrated a
higher level of inbreeding than either of the EU populations. However, none of the case
groups were significantly more inbred than the controls (Supplemental Table S4).
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A GWAS was conducted using 111 affected (case) and 117 unaffected (control) BMD from
NA revealing >20 markers within a single peak of association on CFA11 spanning ~9 Mb
from 38.5–47.1 Mb (praw=1.41×10−9, pemp<1×10−4, 10k permutations) (Figure 2a). After
correcting for population stratification and cryptic relatedness, the most associated marker
was CFA11:47,179,346 (pcorrected=5.6×10−6).
A second GWAS, performed using 125 case and 111 control European BMD, revealed HS
loci on CFA11 at 47.1 Mb (praw=1.5×10−6, pemp=0.0064) and CFA14 from 10.9–14.0 Mb
(praw=9.8×10−8,pemp=0.0003). After correction with EMMA, both loci remained significant
(pcorrected=1.50×10−7 and pcorrected=6.59×10−6, respectively) (Figure 2b).
The datasets were combined and association analysis with correction for population
structure revealed the same two loci as above (Figure 2c), however only the CFA11 locus
was associated in both the individual and combined GWAS. The SNP at CFA11:47,179,346
had the strongest association with disease susceptibility by all methods with
praw=1.11×10−11, pemp<1.00×10−4, and pcorrected =1.76×10−8. Quantile-quantile plots,
showing the distribution of p-values before and after population correction, are shown in
Supplemental figure S5. The top ten associated SNPs from each dataset and analysis method
are listed in Supplemental Table S6, followed by a list of possible candidate genes from the
locus on CFA14 for future studies (Supplemental Table S7).
Fine mapping the CFA11 locus
To refine the locus on CFA11 we genotyped an additional 229 SNPs spanning 9.7 Mb
(Supplemental Table S2) in 327 dogs from the combined BMD dataset and imputed the
genotypes using all 468 dogs. In all populations two markers in complete LD with one
another showed the highest association with pcorrected =4.15×10−12, 3.15×10−8, and
9.90×10−21, in NA, EU, and the combined set, respectively (Supplemental Figure S8). These
markers were located at 44,191,398 and 44,215,162 in the CanFam2 assembly.
Genotypes across the region were phased and multi-marker association computed. All dogs
carrying the case-associated allele at position 44,191,398 carried an identical three SNP
haplotype at positions 44,191,398, 44,215,162, and 44,254,083. The haplotype was common
in BMD, however, and comprised 80% of case haplotypes in all populations, but ranged
from 49% to 64% in controls (Table 1). Strikingly, 65% of cases were homozygous for the
CA haplotype within each population, with >95% of cases carrying the CA haplotype on at
least one chromosome. By comparison, only 18–39% of the controls were homozygous for
the CA haplotype (Table 1).
These three SNPs define a 198kb region (44,133,881-44,331,630) that spans
methylthioadenosine phosphorylase gene (MTAP), and the cyclin dependent kinase
inhibitors 2A (CDKN2A), and 2B (CDKN2B).
Sequencing in NA BMD
We identified 139 informative SNPs by sequencing, including 115 within the 198 kb
haplotype (Supplemental Table S2). Two coding mutations were found in CDKN2A; a silent
mutation in exon 1a and a mutation in exon 2 that is silent in p14ARF but changes an
asparagine to a histidine in p16 INK4a. The altered amino acid is not conserved across
species and the SNP does not segregate with the disease (Fishers exact p=0.09893). A SNP
88 bases upstream of exon 1a, that is likely within the 5′UTR, showed an association with
HS (Fishers exact p=1.09×10−6, pemp=0.00029). However, this SNP alone is unlikely to be
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causative as the associated allele was found in eight of ten dogs from breeds in which HS is
rare (Supplemental Table S3).
Thirty SNPs spanning positions 44,191,314 - 44,293,447 were in complete LD with the two
most highly associated SNPs from the combined GWAS (Figure 3b). The associated
haplotype was reduced to 75,920 bases (44,177,956-44,253,875) including SNPs at positions
44,177,978-44,251,174 surrounding the MTAP gene and ending within intron 2 of
CDKN2A. This haplotype is broken by a single SNP at position 44,232,491 that appears to
have arisen on the CA haplotype. Haplotypes on either side of this SNP are nearly identical
in frequency with only one dog out of 228 being a possible recombinant.
More than 65kb of the 75kb haplotype have been sequenced in the discovery set. The
remaining 10kb is divided among 25 loci ranging from <10 to nearly 2000 bps and is largely
comprised of repetitive elements. Thus far, no single marker or combination of markers
within the 75.9 kb haplotype conveyed significantly more risk than any other (Figure 3a).
LD in dog breeds can be expansive, extending over one Mb at some loci (33, 34). Because
of the near perfect LD found within this disease-associated region, and the lack of coding
mutations, finding the causative mutation remains outside the scope of this paper. However,
functional approaches can be applied to determine the most probable effect of the elusive
mutation(s).
Correlation of haplotype with candidate gene expression
The disease-associated haplotype lies across MTAP and continues through the last exon of
CDKN2A. We performed quantitative real time PCR across the region to determine if there
were changes in transcript levels that correlated with the CA haplotype. Expression was
measured on total RNA from histiocytes cultured from whole blood samples of healthy
BMDs carrying zero, one, or two copies of the CA haplotype. No significant changes in
MTAP expression were observed. However, individuals with two copies of the CA
haplotype produced significantly higher amounts of both CDKN2A and CDKN2B
transcripts, averaging 16 (p=.0173, Wilcoxon rank sum) and four times (p=0.00866) higher,
respectively, compared to those lacking a CA haplotype (Table 2). Heterozygotes had
approximately half the homozygote level of transcript, but the differences were not
significant given the small sample sizes tested. These data suggest that there are variants
within the CA haplotype that affect the expression of the CDKN2A and CDKN2B in HS
susceptible dogs.
Discussion
Dissecting the genetic underpinnings of dendritic cell neoplasms presents unique challenges
to canine and human researchers alike, due to confusion regarding the origin of these
immune cell tumors. While human disorders, such as Langerhans cell histiocytosis, have
been well characterized clinically, etiologies remain elusive. We hypothesized that
identification of susceptibility loci in the BMD would likely reveal genes of interest for both
canine and human disorders, thus leading to a better understanding of the genetic
underpinnings of this complex family of neoplasms.
Our data set was comprised of dogs from one breed but two major geographic areas.
Average Fst values show that these BMD populations differ at a level similar to human
populations from unique European countries (35). This is an order of magnitude lower than
differences found between breeds, yet significant to find global alterations in haplotype and
allele frequencies (8, 36).
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There is slightly higher population-wide heterozygosity in the NA BMD compared to
European BMD; however, individuals are characterized by reduced heterozygosity. The
effect of such population differences is apparent in a complex disorder such as HS. In the
NA population, only one locus segregates with the disease. However, the European
population shows at least two. The second European locus may not be important in the NA
population, or the underlying mutation may be present at such a high frequency it is
approaching fixation. A brief examination of markers across the region shows that all NA
dogs share allele frequencies similar to the cases from Europe, supporting the latter
alternative.
This GWAS study unambiguously localized the major HS locus to a 9.7 Mb region on
CFA11. The advantages of genetic mapping in dogs, where loci are quickly identified with
small numbers of samples, can be offset by the potentially difficult transition from disease-
associated haplotype to causative mutation (37). We compared mapping results from two
populations of the same breed to reduce LD. The European population showed overlapping
association with the NA population in a relatively small region of <200 kb, compared to the
~10 Mb identified in the original GWAS. Extensive sequencing revealed a single 75 kb
disease associated haplotype.
Over 85% of the CA haplotype has been sequenced. The majority of the unsequenced
segments are within the large third intron of MTAP. Expression levels of the CDKN2 genes
show a much greater range in cells from dogs carrying the CA haplotype (SD = 0.0052)
compared to those with control haplotypes (SD = 8.5×10−5). It is formally possible that this
is a consequence of small sample size, more likely it indicates that the causal variant is
present on only a subset of CA haplotypes, and has yet to be discovered. The second
explanation also accounts for the relatively high incidence of risk-associated haplotypes in
unaffected dogs.
Expression analysis suggests that HS is caused by a regulatory mutation(s). Unfortunately,
little is known about regulatory elements in the dog. However, we can compare the canine
locus to the corresponding human region and predict regulatory potential. For example,
based on ENCODE chromatin state predictions from human ChIP-seq data (build NCBI36/
hg18) (38, 39, 40), there is a strong enhancer immediately downstream of MTAP. The
homologous region in the dog contains at least one of the 28 highly associated HS SNPs,
and a region containing a series of SINE elements and repeats that may be amenable to
deletion, insertion or rearrangement in addition to base pair changes, providing an attractive
site for further investigation. Another of the highly associated SNPs, at position 44,215,162,
lies within a second predicted enhancer region.
Our data suggest that variants on a risk-associated haplotype surrounding MTAP and
continuing through exon 3 of CDKN2A affect the expression of both CDKN2A and
CDKN2B. All three of the proteins transcribed from the CDKN2 genes; p16INK4A, p14ARF,
and p15INK4B have unique promoters, but share regulatory elements (reviewed in: (41)).
Loss of the CDKN2A-CDKN2B region through mutation, deletion or silencing is among the
most frequent alterations found in human cancers, including HS (42, 43). In addition, CGH
analysis shows that a region of at least one Mb centered on the CDKN2 locus is lost in
~60% of HS tumors in BMD (44). Though unexpected, increased expression of p16INK4a
and p14ARF has been noted in multiple cancers including prostate, ovarian, cervical and
mammary (45–47) and is typically associated with poor prognosis (48–50). Studies have
suggested that, in these neoplastic cells, p16 inhibits apoptosis, particularly in response to
DNA damage. Further investigation of CDNK2 gene regulation in BMD with and without
HS may better illuminate the roles of these common cancer-associated genes.
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MTAP is important for the salvage of methionine and adenine, encoding an enzyme that
plays a role in polyamine metabolism (51). Recently it has been suggested that MTAP may
also be a tumor suppressor (52). In our study, variants within or near the MTAP gene are
associated with altered expression of CDKN2A/CDKN2B, but not changes in MTAP
expression. Thus, our data offer a new perspective on MTAP’s role in cancer. Specifically,
mutations within MTAP likely lead to dysregulation of CDKN2A/B.
The established importance of the MTAP/CDKN2A/CDKN2B locus in multiple cancer
types, in combination with our finding that naturally occurring sequence variants in BMDs
are associated with expression changes in these genes, suggests that the CA haplotype could
be relevant for susceptibility to multiple cancers. Some 16.9% of U.S. BMD reportedly die
of HS-related causes (Figure 4). Since 38% of a random sample of U.S. BMD (n=53) were
homozygous for the CA haplotype (Supplemental Table S9), we hypothesize that multiple
types of BMD cancer may be related to variants within the MTAP-CDKN2A region. This
concept mimics what has been observed at human chromosome region 9p21, which is
associated with susceptibility to several types of human cancer as well as other complex
disorders (53).
Here we present the first GWAS of HS in any species. Using a population-guided mapping
approach, followed by sequencing, we have identified a 75.9 kb haplotype found in 96% of
all HS affected dogs. This haplotype contains features that affect expression of the
CDKN2A and CDKN2B genes, which may be a primary contributor to histiocytic sarcoma
susceptibility in the BMD. The CA haplotype overlies the MTAP gene and likely contains
one or more variants that alter the expression of INK4A/ARF/INK4B but do not affect
MTAP expression. It is plausible that numerous cancers developed by BMD are associated
with sequence variants in this region. These findings lead us to hypothesize that BMDs are
an excellent system for the study of cancer susceptibility due to INK4A/ARF/INK4B
dysregulation, allowing for systematic studies regarding the role of naturally occurring
sequence variants in this increasingly important locus.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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PCA of BMD populations from Europe and North America. PCs were calculated from
whole genome SNP data in cases and controls from NA and Europe. a) Two distinct yet
overlapping populations are identified when comparing North American (red) and European
(blue) populations (Fst = 0.01). b) Cases and controls are distributed evenly throughout both
populations (Fst=0.001). c) Only one of the top ten principal components differentiates cases
from controls, all others divided the samples along continental lines. NA cases=red fill, NA
controls=blue fill, European cases=red line, European controls=blue line.
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Genome wide analyses of HS in two populations of BMD identify an association on CFA11.
The Y-axis indicates the negative log of the uncorrected p-value. The X- axis shows marker
position from the top of CFA1 through CFAX. a) 240 U.S. BMD with maximum association
at CFA11 bp 41,359,032, praw=1.41 × 10−09. b) 234 European BMD with two peaks of
association, CFA11 bp 47,179,346, praw=1.50 × 10−6 and CFA14, praw=9.80 × 10−8. c) U.S.
and European cohorts combined for a total of 474 dogs with maximum association at
CFA11 bp 47,179,346, praw=1.11 × 10−13. Additional peaks found on chromosomes 2, 5 and
20 are reduced to background levels after correcting for population structure.
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A 75 kb region spanning the MTAP gene and continuing through the last exon of CDKN2A
is highly associated with histiocytic sarcoma. A 195 kb region between CFA11 44,133,500
and 44,328,500 is shown. The X-axes for all plots list the SNPs in order from centromere to
telomere. a) Positions of three genes are shown at the top of the graph. Exons are indicated
as colored rectangles, introns are the connecting lines. Transcripts are indicated as arrows
below gene names. Fisher’s exact association of allele frequency with HS is plotted along
the Y-axis for each SNP. The gray line shows association in the discovery set of 24 cases
and 20 controls with p-values on the right Y-axis. The black line shows association in the
full dataset after imputation, with p-values on the left Y-axis. The red lines show association
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of the haplotypes across the region with the p-values in the left y-axis. b) Pairwise LD plot
was calculated using Haploview. Solid red blocks indicate D′ =1 with a LOD score of 2.
The haplotype block containing 28 of 30 equally associated SNPs is outlined in black.
Another two SNPs form a short 3.4 kb haplotype in the CDKN2B region in perfect LD with
the larger 75kb haplotype. Differences in p-values between the haplotypes are the result of a
single crossover in a control dog.
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Diagnoses for 3,785 BMD who have died since 1995 collected by the Berner Garde
Foundation. Frequency was determined by dividing individual cancers by the total number
of BMD deaths. “Histiocytosis” includes histiocytic sarcomas, malignant histiocytosis,
reactive histiocytoses.
Shearin et al. Page 16











































































































































































































































Shearin et al. Page 18
Table 2
Expression levels of three genes surrounding the case-associated haplotype in healthy dogs showing all three
genotypes.
Genotypea Amountb Increasec Pd
CDKN2A 2 0.002577 16.8988 0.0173
1 0.001334 8.7482 >0.05
0 0.000153 1
CDKN2B 2 0.000697 3.976 0.0087
1 0.000518 2.9567 >0.05
0 0.000175 1
MTAP 2 0.009758 1.2412 >0.05
1 0.009028 1.1484 >0.05
0 0.007862 1
a
The genotype is the number of copies of the case associated (CA) haplotype with 2=homozygous for the CA haplotype, 1=heterozygous, and 0 =
no copies of the CA haplotype.
b
The amount of transcript is relative to the amount of B2M transcript and normalized by comparison to expression in testes.
c
Increase in expression of each gene in individuals carrying the CA haplotype compared to those without.
d
p-values were calculated by Wilcoxon rank sum on the distribution of relative expression levels within each genotype group.
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